Longitudinal plasma proteomic analysis of 1117 hospitalized patients with COVID-19 identifies features associated with severity and outcomes.

Autor:	Viode A; Department of Pathology, Boston Children's Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Smolen KK; Harvard Medical School, Boston, MA, USA.; Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA., van Zalm P; Department of Pathology, Boston Children's Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Neuropsychology and Psychopharmacology, EURON, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, Netherlands., Stevenson D; Department of Pathology, Boston Children's Hospital, Boston, MA, USA., Jha M; Department of Pathology, Boston Children's Hospital, Boston, MA, USA., Parker K; Department of Pathology, Boston Children's Hospital, Boston, MA, USA., Levy O; Harvard Medical School, Boston, MA, USA.; Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.; Broad Institute of MIT & Harvard, Cambridge, MA, USA., Steen JA; Harvard Medical School, Boston, MA, USA.; F. M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, USA.; Neurobiology Program, Boston Children's Hospital, Boston, MA, USA., Steen H; Department of Pathology, Boston Children's Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.; Neurobiology Program, Boston Children's Hospital, Boston, MA, USA.
Jazyk:	angličtina
Zdroj:	Science advances [Sci Adv] 2024 May 24; Vol. 10 (21), pp. eadl5762. Date of Electronic Publication: 2024 May 24.
DOI:	10.1126/sciadv.adl5762
Abstrakt:	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is characterized by highly heterogeneous manifestations ranging from asymptomatic cases to death for still incompletely understood reasons. As part of the IMmunoPhenotyping Assessment in a COVID-19 Cohort study, we mapped the plasma proteomes of 1117 hospitalized patients with COVID-19 from 15 hospitals across the United States. Up to six samples were collected within ~28 days of hospitalization resulting in one of the largest COVID-19 plasma proteomics cohorts with 2934 samples. Using perchloric acid to deplete the most abundant plasma proteins allowed for detecting 2910 proteins. Our findings show that increased levels of neutrophil extracellular trap and heart damage markers are associated with fatal outcomes. Our analysis also identified prognostic biomarkers for worsening severity and death. Our comprehensive longitudinal plasma proteomics study, involving 1117 participants and 2934 samples, allowed for testing the generalizability of the findings of many previous COVID-19 plasma proteomics studies using much smaller cohorts.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu